A new item has been added to the shopping cart

×
×

Tell to a friend

Your Name:
E-mail of your friend:
Message:
Captcha CAPTCHA code
Enter the text in the image above

×

Already a subscriber? Log in now for online Access.

×

Artículo Tomo 71, Número. 4, Mayo 2018

Archivos Españoles de Urología

Something is changing in the diagnosis and treatment of non-muscle invasive bladder cancers (NMIBC)

Authors: Alejandro Sousa Escandˇn.

Arch. Esp. Urol. 2018; 71 (4): 325-327

Vol. 71, Number. 4, May 2018

The most successful treatments in the treatment of NMIBCs have been used for more than 4 decades and are still valid today. Mitomycin C, introduced clinically in 1970 by Shida et al (1), remains the therapy of choice in intermediate and low risk tumors, while BCG, first used by Morales et al (2). In 1976, remains the gold standard. in the treatment of high-grade tumors, even in spite of the important lack of supplies that we have suffered internationally in recent years...



Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |